IODOTOPE
LOE ApproachingNDAORALCAPSULE
Approved
May 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IODOTOPE is an oral capsule containing an iodine-based radiopharmaceutical approved by the FDA in 1957 under NDA status. The specific mechanism of action and therapeutic indications are not documented in available data. This legacy product represents one of the earliest nuclear medicine agents in the pharmaceutical market.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job openings and low competitive pressure (30), suggesting a contracted support team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IODOTOPE offers minimal career growth opportunities with zero linked job openings and a product lifecycle approaching loss of exclusivity. Working on this legacy asset would primarily involve portfolio maintenance, compliance, and transition planning rather than expansive commercial or clinical growth.
Brand ManagerField Sales Representative
Worked on IODOTOPE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.